Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study

Clinical Therapeutics

Volumn 32, Issue 9, 2010, Pages 1664-1673

  Shim, Chi Young ^a   Park, Sungha ^a   Song, Jae Woo ^a   Lee, Sang Hak ^a   Kim, Jung Sun ^a   Chung, Namsik ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Antiplatelet; Clopidogrel; Effect; Safety

Indexed keywords

CLOPIDOGREL;

ADULT; ADVERSE DRUG REACTION; ARTICLE; ASIAN; BIOEQUIVALENCE; BLEEDING TIME; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUTROPHIL COUNT; NORMAL HUMAN; SINGLE DRUG DOSE; SOUTH KOREA; TABLET FORMULATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ADULT; BLEEDING TIME; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TABLETS; THERAPEUTIC EQUIVALENCY; TICLOPIDINE; YOUNG ADULT;

EID: 77958187538     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.08.001     Document Type: Article

References (28)

1. Jarvis B, Simpson K Clopidogrel: A review of its use in the prevention of atherothrombosis. Drugs. 2000, 60:347-377. [published correction appears in Drug. 2001;61:52].
2. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996, 348:1329-1339. CAPRIE Steering Committee.
3. Caplain H, Donat F, Gaud C, Necciari J Pharmacokinetics of Clopidogrel. Semin Thromb Hemost. 1999, Suppl 2:25-28.
4. Maffrand JP, Bernat A, Delebassée D, et al. ADP plays a key role in thrombogenesis in rats. Thromb Haemost. 1988, 59:225-230.
5. Herbert J-M, Savi P, Maffrand J-P Biochemical and pharmacological properties of Clopidogrel: A new ADP receptor antagonist. Eur Heart J Suppls. 1999, 1:A31-A40.
6. Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992, 12:430-436.
7. Savi P, Heilmann E, Nurden P, et al. Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost. 1996, 2:35-42.
8. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of Clopidogrel. DrugMetab Dispos. 2002, 30:1288-1295.
9. Dahl ML, Gunes A Implications of inter-individual differences in Clopidogrel metabolism, with focus on pharmacogenetics. Pharmaceuticals. 2010, 3:782-794. Accessed June 30, 2010. http://www.mdpi.eom/1424-8247/3/4/782/pdf.
10. Krämer HJ, Ulmer HV Reference values for body fat content as a measure for desirable body fat content. Z Ernah-rungswiss. 1984, 23:1-11.
11. Schroeder WS, Ghobrial L, Gandhi PJ Possible mechanisms of drug-induced aspirin and Clopidogrel resistance. J Thromb Thrombolysis. 2006, 22:139-150.
12. Michelson AD, Freiinger AL, Furman MI Current options in platelet function testing. Am J Cardiol. 2006, 98:4N-10N.
13. Guidelines on platelet function testing. J Clin Pathol. 1988, 41:1322-1330. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force.
14. Guideline for Good Clinical Practice. J Postgrad Med. 2001, 47:199-203. ICH Harmonised Tripartite Guideline.
15. Sackett DL, Gent M Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979, 301:1410-1412.
16. Gillings D, Koch G The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inf J. 1991, 25:411-424.
17. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987, 15:657-680.
18. The Rules Governing Medicinal Products in European Community 1991, 3:149-169. European Community, Investigation of Bioavailability and Bioequivalence, (addendum 2). Accessed July 25, 2010. http://www.clindesc.com/Guidelines_online/3%20Clinical/3.1%20General/3_1_2.pdf.
19. Easton JD Benefit of Clopidogrel in patients with symptomatic cerebrovascular disease. Neurology. 1998, 50(Suppl 4):A157.
20. Bhatt DL, Hirsch AT, Chew DP, et al. Marked superiority of Clopidogrel versus aspirin in patients with a history of previous cardiac surgery. J Am Coll Cardiol. 2000, 35(Suppl A):383.
21. Bhatt DL, Marso SP, Hiersch AT, et al. Superiority of Clopidogrel versus aspirin in patients with a history of diabetes mellitus. J Am Coll Cardiol. 2000, 35:409-410.
22. Caro JJ, Migliaccio-Walle K Generalizing the results of clinical trials to actual practice: The example of Clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. Am J Med. 1999, 107:568-572.
23. Müller C, Büttner HJ, Petersen J, Roskamm H A randomized comparison of Clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation. 2000, 101:590-593.
24. Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol. 1999, 34:1884-1890.
25. Thebault JJ, Kieffer G, Cariou R Single-dose pharmacodynamics of Clopidogrel. Semin Thromb Hemost. 1999, 25(Suppl 2):3-8.
26. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999, 25(Suppl 2):15-19.
27. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACQ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006, 47:e1-e121. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary InterventionACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention.
28. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005, 26:804-847. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.